Urothelial tumorigenesis: a tale of divergent pathways (Q36234720)

12 August 2017

1 reference

title

Urothelial tumorigenesis: a tale of divergent pathways (English)

1 reference

12 August 2017

Xue-Ru Wu

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

12 August 2017

published in

Nature Reviews Cancer

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

9

1 reference

12 August 2017

page(s)

713-725

1 reference

Estimating the world cancer burden: Globocan 2000.

12 August 2017

cites work

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Lessons from hereditary colorectal cancer

21 January 2018

1 reference

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

21 January 2018

Focus on bladder cancer

1 reference

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene

21 January 2018

1 reference

Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas

21 January 2018

1 reference

A method to quantitatively detect H-ras point mutation based on electrochemiluminescence

21 January 2018

1 reference

Ras oncogene mutations in urine sediments of patients with bladder cancer.

21 January 2018

1 reference

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

FGFs, their receptors, and human limb malformations: clinical and molecular correlations

21 January 2018

1 reference

Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.

21 January 2018

1 reference

Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.

21 January 2018

1 reference

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia

21 January 2018

1 reference

The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation

21 January 2018

1 reference

The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3

21 January 2018

1 reference

Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein

21 January 2018

1 reference

Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation

21 January 2018

1 reference

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

21 January 2018

1 reference

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients

21 January 2018

1 reference

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

21 January 2018

1 reference

HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder

21 January 2018

1 reference

Cytogenetics and molecular genetics of bladder cancer: a personal view

21 January 2018

1 reference

Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer

21 January 2018

1 reference

Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma

21 January 2018

1 reference

The INK4a/ARF network in tumour suppression

21 January 2018

1 reference

Role of the INK4a locus in tumor suppression and cell mortality.

21 January 2018

1 reference

Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF

21 January 2018

1 reference

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

21 January 2018

1 reference

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

21 January 2018

1 reference

4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene

21 January 2018

1 reference

Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey

21 January 2018

1 reference

Accumulation of nuclear p53 and tumor progression in bladder cancer.

21 January 2018

1 reference

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

21 January 2018

1 reference

Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells

21 January 2018

1 reference

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.

21 January 2018

1 reference

Mdm2: keeping p53 under control

21 January 2018

1 reference

The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.

21 January 2018

1 reference

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer

21 January 2018

1 reference

Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control.

21 January 2018

1 reference

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

21 January 2018

1 reference

Role of T antigen interactions with p53 in tumorigenesis

21 January 2018

1 reference

Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model

21 January 2018

1 reference

CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer

21 January 2018

1 reference

Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway.

21 January 2018

1 reference

Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

21 January 2018

1 reference

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

21 January 2018

1 reference

Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas

21 January 2018

1 reference

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

21 January 2018

1 reference

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

21 January 2018

1 reference

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

21 January 2018

1 reference

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

21 January 2018

1 reference

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

21 January 2018

1 reference

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3.

21 January 2018

1 reference

The potential role of gene therapy in the treatment of bladder cancer

21 January 2018

1 reference

Gene therapy for bladder cancer

21 January 2018

1 reference

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy

21 January 2018

1 reference

Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model

21 January 2018

1 reference

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

21 January 2018

1 reference

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.

21 January 2018

1 reference

Conditional mouse models of sporadic cancer

21 January 2018

1 reference

Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer

21 January 2018

1 reference

p53 and treatment of bladder cancer

21 January 2018

1 reference

Epidemiology and etiology of bladder cancer

21 January 2018

1 reference

Genetic alterations in bladder cancer

31 March 2020

1 reference

Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors

31 March 2020

1 reference

Mutation Affecting the 12th Amino Acid of the c-Ha- ras Oncogene Product Occurs Infrequently in Human Cancer

31 March 2020

1 reference

H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers

31 March 2020

1 reference

A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice.

31 March 2020

1 reference

Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation

31 March 2020

1 reference

Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors

31 March 2020

1 reference

Fibroblast growth factors

31 March 2020

1 reference

Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection

31 March 2020

1 reference

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma

31 March 2020

1 reference

FrequentFGFR3mutations in urothelial papilloma

31 March 2020

1 reference

Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway

31 March 2020

1 reference

Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors

31 March 2020

1 reference

Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses

31 March 2020

1 reference

Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer

31 March 2020

1 reference

Deletion of the p16 and p15 Genes in Human Bladder Tumors

31 March 2020

1 reference

Molecular alterations in bladder cancer

31 March 2020

1 reference

p53 mutations in human bladder cancer: genotypic versus phenotypic patterns

31 March 2020

1 reference

Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder*1

31 March 2020

1 reference

Cell cycle regulators as prognostic factors for bladder cancer

31 March 2020

1 reference

Can p53 staining be used to identify patients with aggressive superficial bladder cancer?

31 March 2020

1 reference

Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer

31 March 2020

1 reference

Lifetime risks of common cancers among retinoblastoma survivors

31 March 2020

1 reference

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

31 March 2020

1 reference

E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder

31 March 2020

1 reference

Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information

31 March 2020

1 reference

Association Between A C/A Single Nucleotide Polymorphism of the E-Cadherin Gene Promoter and Transitional Cell Carcinoma of the Bladder

31 March 2020

1 reference

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family

31 March 2020

1 reference

Farnesyltransferase inhibitors

31 March 2020

1 reference

Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS

31 March 2020

1 reference

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

31 March 2020

1 reference

Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model

31 March 2020

1 reference

Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin.

31 March 2020

1 reference

Pharmacological rescue of mutant p53 conformation and function

31 March 2020

1 reference

CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73

31 March 2020

1 reference

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

31 March 2020

1 reference

Bladder caner from a perspective of 40 years

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC1697

1 reference

12 August 2017

1 reference